$69B CVS-Aetna deal may get regulatory approval soon

Amy Baxter | | Health Exec | Policy & Regulations

CVS Health’s $69 billion takeover of Aetna may soon be greenlit by the U.S. Department of Justice Antitrust Division, according to Reuters, which cited a source familiar with the matter.

The deal brings together one of the nation’s biggest pharmacy retailers and a major health insurance provider.

However, approval may not come in September, according to the source. CVS may need to arrange divestitures to resolve antitrust concerns that may take some time, Reuters reported. 

Another major deal in healthcare was approved by federal regulators earlier this week. Cigna’s $67 billion purchase of Express Scripts cleared the DOJ but still needs regulatory approval from several states.

The CVS deal is being closely watched as one of the most transformative transactions, bringing major industry consolidation. The deal was originally announced at the end of 2017 and is expected to close sometime in the second half of 2018, pending regulatory approval.

See the full story below:

U.S. review of CVS deal for Aetna may end soon: source

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.